KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

In moderately to severely active UC, etrasimod increased remission at 12 and 52 wk but increased adverse events.

Reem Al-Jabri, Waqqas Afif

Ann Intern Med 176(7) JC82

PMID37399559
PMCID-
DOI10.7326/J23-0048
发表日期2023-07-03
摘要

摘要

Sandborn WJ, Vermeire S, Peyrin-Biroulet L, et al. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies. Lancet. 2023;401:1159-1171. 36871574.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。